Sponsor:
RayzeBio, Inc.
Code:
NCT06590857
Conditions
Metastatic Breast Cancer
HER2-negative Breast Cancer
ER+ Breast Cancer
Advanced Breast Cancer
Metastatic Breast Cancer With Bone Involvement
Eligibility Criteria
Sex: All
Age: 0+
Healthy Volunteers: Not accepted
Interventions
RYZ101
Standard of Care Endocrine Therapy
Brief summary:
Conditions
Metastatic Breast Cancer
HER2-negative Breast Cancer
ER+ Breast Cancer
Advanced Breast Cancer
Metastatic Breast Cancer With Bone Involvement
Study ID
NCT06590857
Start date
Jul 19, 2024
Status verified date
Nov, 2026
Completion date
Nov, 2033
Anticipated
Primary completion date
Oct, 2028
Anticipated
Eligibility Criteria
Sex: All
Age: 0+
Healthy Volunteers: Not accepted
Enrollment
64 participants
Anticipated
Allocation
Non randomized
Intervention Model
Sequential
Primary purpose
Treatment
Arms
experimental: Monotherapy Dose Escalation
experimental: Endocrine Therapy Combination Dose Escalation and Expansion
Interventions
RYZ101
Standard of Care Endocrine Therapy
Primary outcome measure
Central contacts
Locations
Research Facility
Recruiting
Santa Monica, California, United States, 90404
Research Facility
Recruiting
Longmont, Colorado, United States, 80504
Research Facility
Recruiting
Indianapolis, Indiana, United States, 46202
Research Facility
Recruiting
Omaha, Nebraska, United States, 68124
Research Facility
Recruiting
Seattle, Washington, United States, 98109
Research Facility
Recruiting
Vancouver, British Columbia, Canada, V5Z 4E6
Sponsor
RayzeBio, Inc.
Last update posted
Nov 18, 2026
Last verified
Nov, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-20. This information was provided to ClinicalTrials.gov by RayzeBio, Inc. on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.